Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2016 May 1.

Published in final edited form as: Immunol Allergy Clin North Am. 2015 Mar 6;35(2):247–260. doi: 10.1016/j.iac.2015.01.009

Fig 2 — Relative abundance of glycosylation patterns on cetuximab at sites Asn88 (A) and Asn299 (B) as resolved by mass spectroscopy The blue sections on the Fab arms indicate the murine segments of the antibody. See Figure 1 for glycan structure notation. Adapted from Ayoub D, Jabs W, Resemann A, et al: Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques. Landes Bioscience 2013, 5(5):699-710.

Fig 2 — Relative abundance of glycosylation patterns on cetuximab at sites Asn88 (A) and Asn299 (B) as resolved by mass spectroscopy The blue sections on the Fab arms indicate the murine segments of the antibody. See Figure 1 for glycan structure notation. Adapted from Ayoub D, Jabs W, Resemann A, et al: Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques. Landes Bioscience 2013, 5(5):699-710.